(Circulation. 2000;102:2341.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Detection of Chlamydia pneumoniae DNA in CD3+ Lymphocytes From Healthy Blood Donors and Patients With Coronary Artery Disease
From the Section of Infectious Diseases, Department of Pediatrics (R.K., J.U., J.W., W.M.W.) and Division of Cardiovascular Medicine, Department of Internal Medicine (S.Y.), University of California, Davis.
Correspondence to Dr Ravi Kaul, Section of Infectious Diseases, Department of Pediatrics, 403 Neurosciences Bldg, 1515 Newton Ct, University of California Davis, Davis, CA 95616. E-mail rkkaul{at}ucdavis.edu
Background—Chlamydia pneumoniae is an intracellular bacterium responsible for respiratory tract infections. Recent studies have implicated this organism in the pathogenesis of atherosclerosis.
Methods and Results—To address how the organism is transported from lungs to cardiac vessels, we characterized the cell population within peripheral blood mononuclear cells (PBMCs) that harbor C pneumoniae DNA. Adherent and nonadherent PBMCs from 28 patients with coronary artery disease (CAD) and 19 healthy blood donors were evaluated for the presence of C pneumoniae DNA by touchdown nested polymerase chain reaction (nPCR). Of the 28 patients, 10 (36%) had detectable PCR product in their nonadherent and 3 (10%) in their adherent PBMC population. C pneumoniae–specific PCR results were positive for 5 of 19 (26%) healthy blood donors. PCR positivity was detected only in the nonadherent cell population among this group of individuals. Fractionation of nonadherent PBMCs identified C pneumoniae–specific PCR signal among the CD3+ T-cell population exclusively. Of the 18 PCR-positive subjects (13 patients and 5 healthy control subjects), 67% (8 patients and 4 healthy blood donors) tested positive for C pneumoniae–specific IgG serology. Interestingly, 2 patients became PCR negative on a repeated blood draw 5 months after initial detection of C pneumoniae DNA despite retaining C pneumoniae–specific antibodies.
Conclusions—Our results demonstrate marginally significant prevalence of C pneumoniae DNA in patients with CAD compared with healthy subjects (P=0.082). In contrast, the prevalence of IgG seropositivity among the 2 groups did not reach statistical significance (P=0.306). We also provide unequivocal evidence for the presence of C pneumoniae DNA predominantly among the circulating CD3+ T-cell population.
Key Words: Chlamydia pneumoniae • atherosclerosis • polymerase chain reaction • cells • lymphocytes
This article has been cited by other articles:
 |
|
 |
|
  H. Ikejima, H. Friedman, G. F. Leparc, and Y. Yamamoto Depletion of Resident Chlamydia pneumoniae through Leukoreduction by Filtration of Blood for Transfusion J. Clin. Microbiol., September 1, 2005; 43(9): 4580 - 4584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Ieven and V. Y. Hoymans Involvement of Chlamydia pneumoniae in Atherosclerosis: More Evidence for Lack of Evidence J. Clin. Microbiol., January 1, 2005; 43(1): 19 - 24. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gieffers, G. van Zandbergen, J. Rupp, F. Sayk, S. Kruger, S. Ehlers, W. Solbach, and M. Maass Phagocytes transmit Chlamydia pneumoniae from the lungs to the vasculature Eur. Respir. J., April 1, 2004; 23(4): 506 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J de Boer, A. E Becker, and A. C van der Wal T lymphocytes in atherogenesis--functional aspects and antigenic repertoire Cardiovasc Res, October 15, 2003; 60(1): 78 - 86. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yamaguchi, H. Friedman, M. Yamamoto, K. Yasuda, and Y. Yamamoto Chlamydia pneumoniae Resists Antibiotics in Lymphocytes Antimicrob. Agents Chemother., June 1, 2003; 47(6): 1972 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Kalayoglu, P. Libby, and G. I. Byrne Chlamydia pneumoniae as an Emerging Risk Factor in Cardiovascular Disease JAMA, December 4, 2002; 288(21): 2724 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C van der Wal Chlamydia pneumoniae inside the atherosclerotic plaque--does it affect plaque inflammation and plaque progression? Cardiovasc Res, November 1, 2002; 56(2): 178 - 180. [Full Text] [PDF]
|
|
|
|
|
|
R Ezzahiri, H.J.M.G Nelissen-Vrancken, H.A.J.M Kurvers, F.R.M Stassen, I Vliegen, G.E.L.M Grauls, M.M.L van Pul, P.J.E.H.M Kitslaar, and C.A Bruggeman Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice Cardiovasc Res, November 1, 2002; 56(2): 269 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q Hao, N Miyashita, M Matsui, H-Y Wang, T Matsushima, and T Saida Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis Multiple Sclerosis, October 1, 2002; 8(5): 436 - 440. [Abstract] [PDF]
|
|
|
|
 |
|
 S. W. Kerrigan, I. Douglas, A. Wray, J. Heath, M. F. Byrne, D. Fitzgerald, and D. Cox A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation Blood, June 28, 2002; 100(2): 509 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Boman and M. R. Hammerschlag Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies Clin. Microbiol. Rev., January 1, 2002; 15(1): 1 - 20. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Haranaga, H. Yamaguchi, H. Friedman, S.-i. Izumi, and Y. Yamamoto Chlamydia pneumoniae Infects and Multiplies in Lymphocytes In Vitro Infect. Immun., December 1, 2001; 69(12): 7753 - 7759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huhtinen, M. Puolakkainen, K. Laasila, M. Sarvas, A. Karma, and M. Leirisalo-Repo Chlamydial Antibodies in Patients with Previous Acute Anterior Uveitis Invest. Ophthalmol. Vis. Sci., July 1, 2001; 42(8): 1816 - 1819. [Abstract] [Full Text] [PDF]
|
|